C4 Therapeutics (CCCC) Income from Continuing Operations: 2019-2025
Historic Income from Continuing Operations for C4 Therapeutics (CCCC) over the last 6 years, with Sep 2025 value amounting to -$32.2 million.
- C4 Therapeutics' Income from Continuing Operations fell 30.41% to -$32.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$119.1 million, marking a year-over-year decrease of 12.88%. This contributed to the annual value of -$105.3 million for FY2024, which is 20.51% up from last year.
- As of Q3 2025, C4 Therapeutics' Income from Continuing Operations stood at -$32.2 million, which was down 23.62% from -$26.0 million recorded in Q2 2025.
- Over the past 5 years, C4 Therapeutics' Income from Continuing Operations peaked at -$15.7 million during Q4 2021, and registered a low of -$35.9 million during Q2 2023.
- In the last 3 years, C4 Therapeutics' Income from Continuing Operations had a median value of -$28.4 million in 2024 and averaged -$29.3 million.
- Its Income from Continuing Operations has fluctuated over the past 5 years, first plummeted by 109.21% in 2021, then soared by 50.68% in 2024.
- Over the past 5 years, C4 Therapeutics' Income from Continuing Operations (Quarterly) stood at -$15.7 million in 2021, then plummeted by 75.07% to -$27.4 million in 2022, then dropped by 26.78% to -$34.8 million in 2023, then rose by 0.52% to -$34.6 million in 2024, then plummeted by 30.41% to -$32.2 million in 2025.
- Its last three reported values are -$32.2 million in Q3 2025, -$26.0 million for Q2 2025, and -$26.3 million during Q1 2025.